IPO registrations (S-1, F-1) · Registrants

Trevi Therapeutics, Inc.

SEC CIK
1563880 · filings on EDGAR ↗
Registration
Form S-1, first filed 2019-04-05, last 2021-08-27; 3 initial registrations, 3 amendments
Outcome
Final prospectus filed 2019-05-08; declared effective 2019-05-07; withdrawal requested 2021-10-08
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
195 CHURCH STREET, 16TH FLOOR, New Haven, CT 06510
EIN
45-0834299
Ticker
TRVI (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
Trevi Therapeutics, Inc. on the corporate pages

Offering terms

Final price
$10.00 per share (424B4 filed 2019-05-08, an initial public offering)
Shares sold
5,500,000
Gross proceeds
$55,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol TRVI
Lead underwriters
Leerink Partners; Stifel; BMO Capital Markets
Syndicate
Needham & Company

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 15

FiledFormWhat it isName as filedEDGAR
2019-04-05S-1S-1 (registration)Trevi Therapeutics, Inc.0001193125-19-099340 ↗
2019-04-22S-1/AS-1/A (amendment)Trevi Therapeutics, Inc.0001193125-19-112820 ↗
2019-05-06S-1/AS-1/A (amendment)Trevi Therapeutics, Inc.0001193125-19-138079 ↗
2019-05-07S-1/AS-1/A (amendment)Trevi Therapeutics, Inc.0001193125-19-138831 ↗
2019-05-07EFFECTEFFECT (declared effective)Trevi Therapeutics, Inc.9999999995-19-001033 ↗
2019-05-08424B4424B4 (final prospectus)Trevi Therapeutics, Inc.0001193125-19-141374 ↗
2020-07-02EFFECTEFFECT (declared effective)Trevi Therapeutics, Inc.9999999995-20-001643 ↗
2021-07-07S-1S-1 (registration)Trevi Therapeutics, Inc.0001193125-21-209928 ↗
2021-07-14EFFECTEFFECT (declared effective)Trevi Therapeutics, Inc.9999999995-21-002767 ↗
2021-08-27S-1S-1 (registration)Trevi Therapeutics, Inc.0001193125-21-259333 ↗
2021-10-08RWRW (withdrawal request)Trevi Therapeutics, Inc.0001193125-21-295518 ↗
2021-10-25EFFECTEFFECT (declared effective)Trevi Therapeutics, Inc.9999999995-21-004024 ↗
2021-11-16EFFECTEFFECT (declared effective)Trevi Therapeutics, Inc.9999999995-21-004369 ↗
2022-05-11EFFECTEFFECT (declared effective)Trevi Therapeutics, Inc.9999999995-22-001421 ↗
2023-08-15EFFECTEFFECT (declared effective)Trevi Therapeutics, Inc.9999999995-23-002394 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2019-05-07S-1/Aregistration statement$10.005,500,000$55,000,000Nasdaq TRVI4primary document; price sentence, shares headline, proceeds computed, cover names 4document ↗
2019-05-08424B4final prospectus$10.005,500,000$55,000,000Nasdaq TRVI4primary document; price sentence, shares headline, proceeds table, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Agger Mette KirstineDirector32019
Aperture Venture Partners IV, L.P.TenPercentOwner22019
Aperture Ventures IV Management, LLCTenPercentOwner22019
BARRIS PETER JTenPercentOwner22019
BASKETT FORESTTenPercentOwner62019–2026
Behbahani AliTenPercentOwner62019–2026
BONDERMAN DAVIDOther; TenPercentOwner82019–2022
Brett-Smith HelenaOfficerChief Development Officer22019–2020
Chang CarmenTenPercentOwner62019–2026
COULTER JAMES GOther; TenPercentOwner82019–2022
Drake Debra ATenPercentOwner22019
DRAKE PETER FTenPercentOwner22019person page Fuzzy
Florence Anthony A. Jr.TenPercentOwner62019–2026
GOOD JENNIFER LDirector,Officer; Director,Officer,TenPercentOwnerPresident and CEO; President & CEO; See Remarks202019–2026
Heffernan Michael ThomasDirector122019–2026
Lundbeckfond Invest A/STenPercentOwner22019
Makhzoumi MohamadTenPercentOwner62019–2026
MAKOWER JOSHUATenPercentOwner32019–2020
Mathers Edward TDirector102019–2026
Mazabraud YannOfficerSee Remarks32019–2020
Meeker David PDirector; Director,TenPercentOwner122019–2026
Mellon Family Investment Co VTenPercentOwner22019
MFIC V, LLCTenPercentOwner22019
Mitsak Anna GuyerDirector32019
MOTT DAVID MTenPercentOwner22019
Muscolo Frank POfficerController42019–2021
Nadav EranDirector22019
NEA 16 GP, LLCTenPercentOwner62019–2026
NEA Partners 16, L.P.TenPercentOwner62019–2026
New Enterprise Associates 16, L.P.TenPercentOwner62019–2026
Omega Fund V GP, L.P.TenPercentOwner22019
Omega Fund V GP Manager, Ltd.TenPercentOwner22019
Omega Fund V, L.P.TenPercentOwner22019
O'Shea William JTenPercentOwner12019
Richard King Mellon FoundationTenPercentOwner22019
SANDELL SCOTT DTenPercentOwner62019–2026
SCIASCIA THOMASOfficer; Officer,TenPercentOwnerChief Medical Officer; Chief Scientific Officer192019–2026
Seiter ChristopherOfficerCFO; Chief Financial Officer42019–2021
Sonsini Peter W.TenPercentOwner52019–2022
TPG Group Holdings (SBS) Advisors, Inc.TenPercentOwner42019–2020
VANLENT ANNEDirector112019–2026
Walker Paul EdwardDirector; TenPercentOwner62019–2026
OSHEA WILLIAM JTenPercentOwner22019
Cassella James VDirector; OfficerChief Development Officer102020–2026
Colangelo DominickDirector92020–2026
Forbes William POfficerChief Development Officer52021–2022
Galletta ChristopherOfficerSee Remarks112021–2026
Delfini LisaOfficerChief Financial Officer192021–2025
TPG GP A, LLCOther; TenPercentOwner52022
WINKELRIED JONOther; TenPercentOwner52022
Clark David JOfficerChief Medical Officer32022–2024
Simon FarrellOfficerChief Commercial Officer92023–2026
HASTINGS DAVID COfficerChief Financial Officer22026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2022-04-18Trevi Therapeutics, Inc.Biotechnology$54,999,998$54,999,998121
2021-10-21Trevi Therapeutics, Inc.Biotechnology$3,000,000$3,000,00011
2021-10-20Trevi Therapeutics, Inc.Biotechnology$11,819,891$11,819,89111
2017-07-24Trevi Therapeutics, Inc.Biotechnology$61,906,460$51,906,460182

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationTREVI THERAPEUTICS, INC.CTState business registriesname and state
Plan sponsorTREVI THERAPEUTICS, INC.CTForm 5500 (employee benefit plans)name and state
Form D issuerTrevi Therapeutics, Inc.CTForm D private offeringsCIK (EXACT)
Patent assigneeTrevi Therapeutics, Inc.CTPatents (USPTO)name and state
SEC filerTrevi Therapeutics, Inc.SEC filers (EDGAR)CIK (EXACT)
Trademark ownerTrevi Therapeutics, Inc.CTTrademarks (USPTO)name and state
Form 5500 plan sponsorTREVI THERAPEUTICS, INC.EIN (EXACT)
Person pagePeter F DrakePeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, CT first:

More with this interest.

In other datasets, the same topic (Health) in CT:

Interests: Pharmaceutical Preparations · Health